Significance of Platinum‐Based Chemotherapy With Programmed Death‐1 Blockade in Limited Disease Small Cell Lung Cancer: A Retrospective Study
Ayako Shiono, Hisao Imai, Kyoichi Kaira, Takanori Abe, Yuki Sato, Ken Yamamoto, Hiroki Watanabe, Yuko Tsuchiya‐Kawano, Akihiro Tamiya, Takashi Osaki, Noriko Yanagitani, Shigeru Tanzawa, Toshiyuki Sumi, Kohei Yoshimine, Yohei Matsui, Satoshi Endo, Kazuhiko Shibata, Shinnosuke Takemoto, Yosuke Miura, Yoshiaki Nagai, Junichi Nakagawa, Takeshi Tsuda, Hiroshi Kagamu
Abstract
1## Introduction Small cell lung cancer (SCLC) accounts for approximately 10%-15% of all lung cancers . SCLC is a highly malignant tumor that grows rapidly and can cause lymph node and distant metastases at an early stage; however, it is characterized by its high sensitivity to radiotherapy and chemotherapy. Patients who receive initial chemotherapy and chest radiotherapy for limited disease (LD)-SCLC show a good response, but the 5-year survival rate is < 30% . The standard treatment for LD-SCLC is a combination of chemotherapy and thoracic radiotherapy, followed by prophylactic cranial irrad
§ The Valyu brief
Reading the full paper and taking notes. This takes a few seconds…
§ Ask this paper
Ask a question about this paper
Valyu reads the full text and answers from what the paper actually says.
Searching the other archives…